Dana Investment Advisors Inc. Has $5.83 Million Stock Holdings in Johnson & Johnson $JNJ

Dana Investment Advisors Inc. cut its stake in Johnson & Johnson (NYSE:JNJ) by 9.5% in the 3rd quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 31,457 shares of the company’s stock after selling 3,306 shares during the period. Dana Investment Advisors Inc.’s holdings in Johnson & Johnson were worth $5,833,000 at the end of the most recent quarter.

Several other hedge funds have also recently bought and sold shares of the company. Stonebrook Private Inc. increased its stake in shares of Johnson & Johnson by 2.7% in the 3rd quarter. Stonebrook Private Inc. now owns 24,101 shares of the company’s stock valued at $4,469,000 after purchasing an additional 640 shares during the last quarter. EverSource Wealth Advisors LLC raised its stake in shares of Johnson & Johnson by 2.7% during the third quarter. EverSource Wealth Advisors LLC now owns 15,098 shares of the company’s stock valued at $2,800,000 after acquiring an additional 398 shares during the last quarter. Cornerstone Capital Inc. grew its stake in shares of Johnson & Johnson by 1.8% in the third quarter. Cornerstone Capital Inc. now owns 99,373 shares of the company’s stock worth $18,426,000 after purchasing an additional 1,714 shares during the last quarter. Cary Street Partners Investment Advisory LLC increased its holdings in Johnson & Johnson by 20.4% in the third quarter. Cary Street Partners Investment Advisory LLC now owns 4,116 shares of the company’s stock valued at $763,000 after purchasing an additional 698 shares during the period. Finally, Fortis Capital Management LLC grew its position in shares of Johnson & Johnson by 3.7% in the 3rd quarter. Fortis Capital Management LLC now owns 5,449 shares of the company’s stock valued at $1,010,000 after buying an additional 192 shares during the last quarter. 69.55% of the stock is owned by institutional investors.

Insider Transactions at Johnson & Johnson

In related news, EVP Timothy Schmid sold 22,623 shares of the company’s stock in a transaction on Wednesday, February 18th. The stock was sold at an average price of $244.33, for a total transaction of $5,527,477.59. Following the completion of the sale, the executive vice president owned 26,769 shares in the company, valued at approximately $6,540,469.77. This represents a 45.80% decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which can be accessed through this link. Also, EVP Vanessa Broadhurst sold 6,197 shares of the stock in a transaction on Tuesday, February 17th. The shares were sold at an average price of $243.39, for a total value of $1,508,287.83. Following the completion of the sale, the executive vice president directly owned 23,003 shares of the company’s stock, valued at $5,598,700.17. The trade was a 21.22% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. Insiders have sold a total of 30,142 shares of company stock valued at $7,360,528 in the last quarter. Company insiders own 0.16% of the company’s stock.

Analysts Set New Price Targets

Several research firms recently issued reports on JNJ. Sanford C. Bernstein boosted their target price on shares of Johnson & Johnson from $208.00 to $225.00 and gave the company a “market perform” rating in a report on Friday, January 23rd. Daiwa Securities Group upped their target price on Johnson & Johnson from $203.00 to $237.00 and gave the company an “outperform” rating in a research report on Thursday, January 29th. Bank of America raised their target price on Johnson & Johnson from $220.00 to $221.00 and gave the stock a “neutral” rating in a research note on Thursday, January 22nd. Rothschild & Co Redburn boosted their price target on Johnson & Johnson from $180.00 to $210.00 and gave the company a “neutral” rating in a research note on Thursday, February 19th. Finally, Stifel Nicolaus raised their price objective on shares of Johnson & Johnson from $205.00 to $220.00 and gave the stock a “hold” rating in a research report on Thursday, January 22nd. One equities research analyst has rated the stock with a Strong Buy rating, seventeen have given a Buy rating and nine have assigned a Hold rating to the company’s stock. According to MarketBeat.com, Johnson & Johnson currently has an average rating of “Moderate Buy” and an average price target of $232.70.

Key Headlines Impacting Johnson & Johnson

Here are the key news stories impacting Johnson & Johnson this week:

• Positive Sentiment: Regulatory/clinical catalyst — J&J submitted an sBLA for IMAAVY (nipocalimab) seeking the first FDA‑approved therapy for warm autoimmune hemolytic anemia, supported by positive pivotal ENERGY trial results; an approval would add a new, high‑value orphan indication. Johnson & Johnson seeks FDA approval of IMAAVY (PR Newswire)
• Positive Sentiment: Strategic growth story — coverage notes J&J’s pivot to high‑margin MedTech, strong oncology momentum (Darzalex) and Tremfya data, and a roadmap to ~$100B revenue — a narrative that supports multiple buyers seeking defensive growth and yield. Boring Is Beautiful: Why Johnson & Johnson Is Beating the Tech Sector
• Positive Sentiment: Clinical durability for key immunology franchise — new three‑year TREMFYA ulcerative colitis data showing sustained outcomes bolsters confidence in J&J’s ability to offset older drug losses with high‑growth franchises. Johnson & Johnson presents three-year TREMFYA data (MSN)
• Neutral Sentiment: Dividend mechanics — the stock recently went ex‑dividend (quarterly $1.30), a technical event that can create short‑term price movement unrelated to fundamentals; income investors may view dips as buying opportunities. Boring Is Beautiful: Why Johnson & Johnson Is Beating the Tech Sector
• Neutral Sentiment: Mixed market signals — analyst notes and options activity are generally upbeat but varied; some price targets have been raised while other coverage is cautious, so near‑term volatility may persist. Wall Street Bulls Look Optimistic About Johnson & Johnson (Zacks)
• Negative Sentiment: Legal overhang — Bayer filed a lawsuit against J&J/Janssen over marketing claims tied to a prostate cancer drug, introducing potential reputational and litigation risk for the biotech unit (timing and financial exposure are uncertain). Bayer files lawsuit against Johnson & Johnson, Janssen Biotech (Reuters)
• Negative Sentiment: Insider selling — EVP Timothy Schmid disclosed recent sales (Form 4 filings), which some investors interpret as profit‑taking and can weigh on sentiment despite being routine. SEC filing: Form 4 (Insider Sale)

Johnson & Johnson Trading Up 0.2%

Shares of Johnson & Johnson stock opened at $246.21 on Wednesday. The stock has a market capitalization of $593.35 billion, a PE ratio of 22.28, a price-to-earnings-growth ratio of 2.39 and a beta of 0.35. Johnson & Johnson has a 52 week low of $141.50 and a 52 week high of $247.25. The stock has a 50 day moving average price of $222.42 and a two-hundred day moving average price of $200.48. The company has a debt-to-equity ratio of 0.48, a quick ratio of 0.77 and a current ratio of 1.03.

Johnson & Johnson (NYSE:JNJ) last issued its earnings results on Saturday, January 31st. The company reported $2.46 earnings per share (EPS) for the quarter. Johnson & Johnson had a return on equity of 33.04% and a net margin of 28.46%.The company had revenue of $24.28 billion for the quarter. As a group, equities analysts anticipate that Johnson & Johnson will post 10.58 earnings per share for the current fiscal year.

Johnson & Johnson Dividend Announcement

The firm also recently announced a quarterly dividend, which will be paid on Tuesday, March 10th. Investors of record on Tuesday, February 24th will be issued a $1.30 dividend. This represents a $5.20 dividend on an annualized basis and a dividend yield of 2.1%. The ex-dividend date is Tuesday, February 24th. Johnson & Johnson’s dividend payout ratio is currently 47.06%.

Johnson & Johnson Company Profile

Johnson & Johnson is a multinational healthcare company headquartered in New Brunswick, New Jersey, that develops, manufactures and markets a broad range of products across pharmaceuticals, medical devices and previously consumer health. Founded in 1886 by the Johnson family, the company has grown into a global healthcare organization with operations and sales in many countries around the world.

The company’s pharmaceuticals business, organized largely under its Janssen research and development organization, focuses on prescription medicines across therapeutic areas such as immunology, infectious disease, oncology and neuroscience.